Clerk of the House of Representatives Legislative Resource Center B-106 Cannon Building

Washington, DC 20515

Signature_

Printed Name and Title

Secretary of the Senate Office of Public Records 232 Hart Building Washington, DC 20510



02 AUG 15 AM 11: 2

LOBBYING REPORT Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required To Complete This Page 1. Registrant Name The Harbour Group, LLC Check if different than previously reported 2. Address 3000 K Street, N.W, Suite 105 3. Principal Place of Business (if different from line 2) 20007 D.C. Washington State/Zip (or Country) E-mail 5. Senate ID Telephone 4. Contact Name (optional) 66636 (202) 295-8787 Joel Johnson 6. House II Self 7. Client Name Pharmaceutical Research and Manufacturers of America (PhRMA) TYPE OF REPORT 8. Year 2002 Midyear (January 1-June 30) OR Year End (July 1-Decembe 9. Check if this filing amends a previously filed version of this report 11. No Lobbying A Termination Date 10. Check if this is a Termination Report **INCOME OR EXPENSES -** Complete Either Line 12 **OR** 13 13. Organizations 12. Lobbying Firms **EXPENSES** relating to lobbying activities for this rep INCOME relating to lobbying activities for this reporting period were: period was: Less than \$10,000 Less than \$10,000 s 100.000 \$10,000 or more \$10,000 or more Income (nearest \$20,000) Provide a good faith estimate, rounded to the nearest \$20,000, of 14. REPORTING METHOD. Check box to indicate expe all lobbying related income from the client (including all method. See instructions for description of options. payments to the registrant by any other entity for lobbying activities on behalf of the client). Method A. Reporting amounts using LDA definit Reporting amounts under section 603 ☐ Method B. Internal Revenue Code ☐ Method C. Reporting amounts under section Internal Revenue Code

Joel Johnson, Mananging Director

Filing #70a2d26d-7eff-42cf-9016-59b12c4ae2e3 - Page 1 of 8

LD-2 (REV. 6/98)

Registrant Name The Harbour Group,	LLC Cli	ent Name	PhRMA	
LOBBYING ACTIVITY. Select as engaged in lobbying on behalf of the information as requested. Attach add	client during the	reporting p	o reflect the general reriod. Using a se	al issue areas in which t parate page for each c
15. General issue area code	MMM	_ (one per	page)	
16. Specific lobbying issues				
Matters affecting the pharmaceut	ical industry and p	oharmaceu	tical research	
17. House(s) of Congress and FederU.S. House of RepresentationU.S. Senate	-	cted	☐ Check	if None
18. Name of each individual who	acted as a lobby	ist in this		Position (if applicable)
			,	
Joel Johnson			Advisor to the Presidunications	
19. Interest of each foreign entity in	the specific issue	es listed or	ı line 16 above	☑ Check if None
Signature			Date	8/14/02

Toel Johnson Managing Director Filing #70a2d26d-7eff-42cf-9016-59b12c4ae2e3 - Page 3 of 8

Page

Registrant Name The Harbour Group, LLC	_ Client NamePhRMA
LOBBYING ACTIVITY. Select as many codes engaged in lobbying on behalf of the client during information as requested. Attach additional page(s	as necessary to reflect the general issue areas in which the reporting period. Using a separate page for each cas) as needed.
15. General issue area code PHA	(one per page)
16. Specific lobbying issues	
Matters affecting the pharmaceutical industry	and pharmaceutical research
17. House(s) of Congress and Federal agencies of U.S. House of Representatives U.S. Senate	ontacted
18. Name of each individual who acted as a lo	bbyist in this issue area
Name	Covered Official Position (if applicable)
Joel Johnson	Senior Advisor to the President for Policy and Communications
19. Interest of each foreign entity in the specific	issues listed on line 16 above
Signature	Date8/14/02
Direct Name of Title Heal Johnson Managing	Director

Toel Johnson Managing Director Filing #70a2d26d-7eff-42cf-9016-59b12c4ae2e3 - Page 5 of 8

Form LD-2 (Rev. 6/98)

Page

Registrant Name The Harbour Group, LLC	Client NamePhRMA
LOBBYING ACTIVITY. Select as many engaged in lobbying on behalf of the client of information as requested. Attach additional	codes as necessary to reflect the general issue areas in which luring the reporting period. Using a separate page for each page(s) as needed.
15. General issue area codeHCR	(one per page)
16. Specific lobbying issues	
Matters affecting the pharmaceutical inc	lustry and pharmaceutical research
17. House(s) of Congress and Federal ager	ncies contacted
U.S. House of Representatives U.S. Senate	
18. Name of each individual who acted	as a lobbyist in this issue area
Name	Covered Official Position (if applicable)
Joel Johnson	Senior Advisor to the President for Policy and Communications
	.
	···· ···
19. Interest of each foreign entity in the sp	pecific issues listed on line 16 above
Signature	Date8/14/02

Form LD-2 (Rev. 6/98)
Page